In vitro activity of imipenem/relebactam against Gram-negative ESKAPE pathogens isolated in 17 European countries: 2015 SMART surveillance programme | Zendy

James A. Karlowsky | Zendy; Sibylle Lob | Zendy; Krystyna M. Kazmierczak | Zendy; Stephen Hawser | Zendy; Sophie Magnet | Zendy; Katherine Young | Zendy; Mary Motyl | Zendy; Daniel F. Sahm | Zendy

Open Access

In vitro activity of imipenem/relebactam against Gram-negative ESKAPE pathogens isolated in 17 European countries: 2015 SMART surveillance programme

Author(s) -

James A. Karlowsky,

Sibylle Lob,

Krystyna M. Kazmierczak,

Stephen Hawser,

Sophie Magnet,

Katherine Young,

Mary Motyl,

Daniel F. Sahm

Publication year - 2018

Publication title -

journal of antimicrobial chemotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.124

H-Index - 194

eISSN - 1460-2091

pISSN - 0305-7453

DOI - 10.1093/jac/dky107

Subject(s) - imipenem , acinetobacter baumannii , microbiology and biotechnology , pseudomonas aeruginosa , klebsiella pneumoniae , broth microdilution , acinetobacter , biology , carbapenem , enterobacter , enterobacteriaceae , antimicrobial , minimum inhibitory concentration , antibiotic resistance , bacteria , antibiotics , escherichia coli , biochemistry , genetics , gene

Relebactam is an inhibitor of class A β-lactamases, including KPC β-lactamases, and class C β-lactamases, and is currently under clinical development in combination with imipenem. The objective of the current study was to evaluate the in vitro activity of imipenem/relebactam against Gram-negative ESKAPE pathogens (Klebsiella pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa and Enterobacter spp.) submitted by clinical laboratories in 17 European countries to the Study for Monitoring Antimicrobial Resistance Trends (SMART) global surveillance programme in 2015.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research